Measures in the first year of therapy predict the response to interferon β in MS
- 19 June 2009
- journal article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 15 (7), 848-853
- https://doi.org/10.1177/1352458509104591
Abstract
Background and objectiveKeywords
This publication has 26 references indexed in Scilit:
- Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon β-1a: analysis of the PRISMS studyMultiple Sclerosis Journal, 2008
- Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patientsMultiple Sclerosis Journal, 2008
- Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patientsAnnals of Neurology, 2006
- Defining interferon β response status in multiple sclerosis patientsAnnals of Neurology, 2004
- Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-?1a in relapsing-remitting multiple sclerosisAnnals of Neurology, 1999
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosisAnnals of Neurology, 1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993